Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?

COI Statement

JMS declares institutional grants unrelated to the current Comment from the National Institute for Health Research UCL Hospitals Biomedical Research Centre, Alzheimer's Association, Alzheimer's Research UK, the UK Medical Research Council, the LifeArc Foundation, and the British Heart Foundation. He also declares royalties from Oxford University Press and Henry Stewart Talks; consulting fees from Eli Lilly, Roche, and Biogen; payment or honoraria from Eli Lilly and Roche; support for attending meetings or travel expenses from Alzheimer's Association, American Academy of Neurology, Alzheimer's Research UK, and Eli Lilly, and the role of Chief Medical Officer at Alzheimer's Research UK.